Market Overview

Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey

Share:
Related BIIB
Biogen: 'A Nice Little Trade' Or Heading To New Lows?
Biogen And Gilead Sciences Catch The Eye Of Short Sellers
Biogen Wins Round In Patent Fight Vs. Kyle Bass (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst Marshall Urist reiterated an Overweight rating on Biogen Idec (NASDAQ: BIIB).

In the report, Urist noted, “Our AlphaWise survey of 121 neurologists in the US and Europe (performed in the month prior to Tecfidera approval) supports a strong launch, $4B+ in sales potential for Biogen's Tecfidera, and our Overweight rating. Roughly half of patients are expected to be on oral therapies within 4-6 years. This implies $4B+ in global sales assuming Tecfidera gains at least 50-60% of the oral segment, which is at the high end of long-term consensus of $3.4-4B. Of note, ABCR share declines from ~80% to ~30% while the high-efficacy segment gains 15% share over this period.”

Biogen Idec closed on Thursday at $217.30.

Latest Ratings for BIIB

DateFirmActionFromTo
Aug 2015H.C. WainwrightInitiates Coverage onBuy
Jul 2015BairdDowngradesOutperformNeutral
Jul 2015Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BIIB)

Get Benzinga's Newsletters